ClinicalTrials.gg
RecruitingNCT06302595Updated Dec 3, 2025

MRI Guided Prostate Biopsy

An interventional study of MRI-guided prostate biopsy using the needle holder frame. in Suspected Prostate Cancer, sponsored by Brigham and Women's Hospital. Recruiting at 1 site in United States. Open to male participants aged 30 Years and older. Per ClinicalTrials.gov, last updated 2025-12-03.

Sponsored by Brigham and Women's Hospital · Not applicable, Interventional, and Device feasibility

How we know

From the registry’s dates

  • Primary completion was expected by Jun 2026, 5 months ago, but the record still lists the study as recruiting.
  • Registered 5 months after the study started (first participant enrolled Aug 2023, registered Feb 2024).
  • Started Aug 2023; still recruiting 3 years 2 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
15
Allocation
Not applicable
Ages
30 Years and older
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital — 9 open to participants now, 12 under way, 1 of them phase 3. Prostatic Neoplasms · Brigham and Women's Hospital.

Planned enrollment
14th of 15
15 · median 36
Started
2023
with 2 others
No phase
8 of 16
4 open now
Primary completion
2026-06
later than 1 of 11 live
Registered
11th of 16
by date

Among the 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital, this one is the 14th largest by planned enrollment of the 15 interventional ones that give a count, is one of 3 that started in 2023, is one of 8 with no phase, reaches primary completion later than 1 of the 11 other live ones, and was the 11th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

9 of the 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital are open now, in 1 country. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 9 open studies →

Where they have run

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 30 Years and older · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies in Prostatic Neoplasms by Brigham and Women's Hospital, or all of them as a file.
02

Study summary

This study aims to assess the feasibility of magnetic resonance (MR) guided prostate biopsy using a needle holder frame. This frame is used to help position the needle used for the biopsy. The feasibility in this study is defined as whether the needle holder frame enables accurate tissue sampling from a suspicious region in the prostate found on an MR image. If it does, a biopsy can be carried out with the needle holder frame safely in a clinical routine. The study will be conducted during a routine MR-guided prostate biopsy procedure with an investigational needle holder frame instead of a conventional needle-guiding template.

Read the detailed description

The study will be conducted during a routine MR-guided prostate biopsy procedure. The following protocol follows the workflow of the routine procedure, except that the needle holder frame is used in place of a conventional needle-guiding template. The treating physicians have decided that an MR-guided prostate biopsy is necessary under the participant's current condition. If the participant chooses to participate in this research study, the procedure will be done in an MR scanner with an investigational needle holder frame.

Before the MR-guided prostate biopsy, the participant already had a standard clinical prostate MRI, the images from which will be used during the procedure.

The MR-guided prostate biopsy procedure may require monitored anesthesia or sedation. The participant will meet with the study physician prior to the biopsy procedure. The study physician will decide the type of monitored anesthesia or sedation to be used in discussion with the participant.

When undergoing a study in the MRI system, the participant will lie motionless inside the gantry of the system. Occasionally, the machine will produce a loud banging noise, as if it were being pounded from the outside with a hammer. Earplugs are available to reduce this sound level.

While the participant is in the magnet, under the anesthetic, the study physician will do the biopsy. To do this, the study physician will use a needle holder frame, which will show us where to put the needle by lining up the correct place outside on the skin or rectal wall.

Like the routine procedure, the biopsy is done with a needle put through the skin under the participant's scrotum by the doctor. The location of the needle is confirmed by acquiring an MR image (confirmation image). Several biopsies are taken each time, from either side of the gland and from places where the MR images show shadows or abnormal areas. There can be a range of 6-15 locations to sample. Because the location of the needle is always confirmed on the confirmation image, like the routine procedure, the use of the needle holder frame will not compromise the sampling of MR-indicated abnormal areas. The participant will be in the study for about 1.5 hours, which is how long the biopsy procedure will take. After the procedure, the investigator will review the confirmation images to assess the accuracy of needle placement, though it will not change the health outcome (e.g., pathological findings).

03

Conditions studied

  • Suspected Prostate Cancer

Browse trials for

Keywords

  • prostate cancer
  • prostate biopsy
  • MR-guided prostate biopsy
  • targeted biopsy
04

Who can participate

Ages eligible
30 Years and older
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Either an abnormal serum prostate-specific antigen (PSA) level (> 4ng/Ml) or a palpable nodule in the prostate on digital rectal examination or prostate MRI suspicious lesion..
  • Diagnostic MRI of the prostate gland.
  • Age > 30 years
  • Signed .
  • No to MRI, i.e. no cardiac pacemaker.
  • No recent or ongoing active ischemic heart disease.

Exclusion criteria

Exclusion Criteria:

  • Inability to give .
  • to MRI- cardiac pacemaker, inner ear implants, non-MR compatible intracranial aneurysm clips.
  • Recent or ongoing active ischemic heart disease such as recent or ongoing angina.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Device feasibility
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
15 participants (estimated)

Study arms

  • Experimental
    MRI-guided prostate biopsy

    Participants who receive biopsy under MRI-guidance and a needle holder frame.

    Device: MRI-guided prostate biopsy using the needle holder frame.

Interventions

  • DeviceMRI-guided prostate biopsy using the needle holder frame.

    A needle holding frame will be used during a routine MRI-guided prostate biopsy procedure, where tissue samples are obtained from each suspected region found on MRI using an MRI-conditional core biopsy needle. In this routine procedure, tissue sampling is performed in an MRI gantry and intraprocedural MRI is used to localize the regions.

06

What researchers measure

Primary outcomes

  1. Accuracy of needle placement

    The number of biopsy failures (defined as the number of needle insertions that miss the target zone defined on MRI).

    Time frame: During the MRI-guided prostate biopsy procedure

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2023 (actual). Primary completion is estimated for Jun 2026, 34 months after the start.

Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 34 months is below that.

Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 15, 2024
First posted
Mar 12, 2024
StartActual
Aug 24, 2023
Primary completionEst.
Jun 2026
CompletionEst.
Jun 2026
Last update
Dec 3, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 3, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06302595
Collaborators
National Cancer Institute (NCI), Physical Sciences Inc.
Responsible party
Kemal Tuncali, M.D. (Assistant Professor of Radiology, Brigham and Women's Hospital) — Principal investigator
First posted
Mar 12, 2024
Start date
Aug 24, 2023
Primary completion
Jun 2026 (estimated)
Completion
Jun 2026 (estimated)
Last update
Dec 3, 2025

Study contacts

Kemal Tuncali, MD
Contact
ktuncali@bwh.harvard.edu
(617) 732-7631
Kemal Tuncali, MD
principal investigator · Brigham and Women's Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion